Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Eckert, Nadine ^a   Wrensch, Florian ^a   Gärtner, Sabine ^a   Palanisamy, Navaneethan ^a   Goedecke, Ulrike ^a   Jäger, Nils ^a   Pöhlmann, Stefan ^a   Winkler, Michael ^a  

^a GERMAN PRIMATE CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAUSSIA LUCIFERASE; HEMAGGLUTININ; IFITM1 PROTEIN; IFITM2 PROTEIN; IFITM3 PROTEIN; MEMBRANE PROTEIN; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; TMPRSS2 PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; ZANAMIVIR; DIFFERENTIATION ANTIGEN; LEU-13 ANTIGEN; LUCIFERASE; PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENDOSOME; ENZYME ACTIVITY; ENZYME RELEASE; GENE ACTIVITY; GENE EXPRESSION; GENETIC STABILITY; INFLUENZA A; INFLUENZA VIRUS A; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; VIROGENESIS; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSMISSION; ANIMAL; BIOASSAY; COPEPOD; DIAGNOSTIC USE; DRUG EFFECTS; ENZYMOLOGY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); VIROLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; CLONING, MOLECULAR; COPEPODA; GENES, REPORTER; GENETIC ENGINEERING; GENETIC VECTORS; INFLUENZA A VIRUS; LUCIFERASES; PROTEINS; VIROLOGY; VIRUS REPLICATION; ZANAMIVIR;

EID: 84901335448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097695     Document Type: Article

References (58)

1. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82-S87.
2. Osterhaus A, Fouchier R, Rimmelzwaan G (2011) Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci 366: 2766-2773.
3. DiazGranados CA, Denis M, Plotkin S (2012) Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 31: 49-57.
4. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
5. Samson M, Pizzorno A, Abed Y, Boivin G (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98: 174-185.
6. Matrosovich M, Matrosovich T, Garten W, Klenk HD (2006) New low-viscosity overlay medium for viral plaque assays. Virol J 3: 63.
7. Gog JR, Afonso ES, Dalton RM, Leclercq I, Tiley L, et al. (2007) Codon conservation in the influenza A virus genome defines RNA packaging signals. Nucleic Acids Res 35: 1897-1907. (Pubitemid 47061658)
8. Neumann G, Watanabe T, Kawaoka Y (2000) Plasmid-driven formation of influenza virus-like particles. J Virol 74: 547-551. (Pubitemid 30002939)
9. Bloom JD, Gong LI, Baltimore D (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
10. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, et al. (2008) Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454: 890-893.
11. Machado AV, Naffakh N, Van Der Werf S, Escriou N (2003) Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter. Virology 313: 235-249. (Pubitemid 37013607)
12. Vieira MA, Naffakh N, Gerbaud S, Van Der Werf S, Escriou N (2006) Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 59 terminal sequence: induction of heterospecific B and T cell responses in mice. Virology 345: 73-87. (Pubitemid 43107574)
13. Li F, Feng L, Pan W, Dong Z, Li C, et al. (2010) Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment. J Virol 84: 12075-12081.
14. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, et al. (2010) Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 107: 11531-11536.
15. Ito K, Chiba S (2013) Arrest peptides: cis-acting modulators of translation. Annu Rev Biochem 82: 171-202.
16. Sun X, Whittaker GR (2013) Entry of influenza virus. Adv Exp Med Biol 790: 72-82.
17. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, et al. (2009) The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243-1254.
18. Everitt AR, Clare S, Pertel T, John SP, Wash RS, et al. (2012) IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484: 519-523.
19. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, et al. (2013) The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13: 452-464.
20. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, et al. (2013) The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 87: 7837-7852.
21. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97: 6108-6113. (Pubitemid 30367531)
22. Bernard P, Couturier M (1992) Cell killing by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes. J Mol Biol 226: 735-745.
23. Miki T, Park JA, Nagao K, Murayama N, Horiuchi T (1992) Control of segregation of chromosomal DNA by sex factor F in Escherichia coli. Mutants of DNA gyrase subunit A suppress letD (ccdB) product growth inhibition. J Mol Biol 225: 39-52.
24. Engler C, Kandzia R, Marillonnet S (2008) A one pot, one step, precision cloning method with high throughput capability. PLoS One 3: e3647.
25. Unger T, Jacobovitch Y, Dantes A, Bernheim R, Peleg Y (2010) Applications of the Restriction Free (RF) cloning procedure for molecular manipulations and protein expression. J Struct Biol 172: 34-44.
26. Tannous BA (2009) Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 4: 582-591.
27. Klenk HD, Rott R, Orlich M, Blodorn J (1975) Activation of influenza A viruses by trypsin treatment. Virology 68: 426-439.
28. Ataei F, Hosseinkhani S, Khajeh K (2009) Limited proteolysis of luciferase as a reporter in nanosystem biology: a comparative study. Photochem Photobiol 85: 1162-1167.
29. Bottcher E, Freuer C, Steinmetzer T, Klenk HD, Garten W (2009) MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 27: 6324-6329.
30. Bertram S, Glowacka I, Blazejewska P, Soilleux E, Allen P, et al. (2010) TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J Virol 84: 10016-10025.
31. Zhirnov O, Klenk HD (2003) Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells. Virology 313: 198-212. (Pubitemid 37013604)
32. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, et al. (2005) Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49: 4075-4084.
33. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, et al. (2005) Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 43: 4139-4146. (Pubitemid 41129710)
34. Triana-Baltzer GB, Gubareva LV, Klimov AI, Wurtman DF, Moss RB, et al. (2009) Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 4: e7838.
35. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, et al. (2011) Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7: e1001258.
36. Bailey CC, Huang IC, Kam C, Farzan M (2012) Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8: e1002909.
37. Cenedella RJ (2009) Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 44: 477-487.
38. Mostafa A, Kanrai P, Ziebuhr J, Pleschka S (2013) Improved dual promotor-driven reverse genetics system for influenza viruses. J Virol Methods 193: 603-610.
39. Evdokimov AG, Pokross ME, Egorov NS, Zaraisky AG, Yampolsky IV, et al. (2006) Structural basis for the fast maturation of Arthropoda green fluorescent protein. EMBO Rep 7: 1006-1012. (Pubitemid 44480515)
40. Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, et al. (2004) Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 324: 67-73. (Pubitemid 38737400)
41. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, et al. (2013) In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281.
42. Tran V, Moser LA, Poole DS, Mehle A (2013) Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread. J Virol 87: 13321-13329.
43. Pan W, Dong Z, Li F, Meng W, Feng L, et al. (2013) Visualizing influenza virus infection in living mice. Nat Commun 4: 2369.
44. Tisdale M (2000) Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 10: 45-55.
45. Okomo-Adhiambo M, Sheu TG, Gubareva LV (2013) Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir Viruses 7 Suppl 1: 44-49.
46. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
47. Diamond MS, Farzan M (2013) The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 13: 46-57.
48. Siegrist F, Ebeling M, Certa U (2011) The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res 31: 183-197.
49. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, et al. (2011) Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343.
50. Cote M, Misasi J, Ren T, Bruchez A, Lee K, et al. (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348.
51. Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, et al. (2013) Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One 8: e56265.
52. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martinez-Sobrido L, et al. (2007) Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A 104: 6806-6811. (Pubitemid 47175582)
53. Zimmermann P, Manz B, Haller O, Schwemmle M, Kochs G (2011) The viral nucleoprotein determines Mx sensitivity of influenza A viruses. J Virol 85: 8133-8140.
54. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146: 2275-2289. (Pubitemid 34682391)
55. Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, et al. (2013) TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol 87: 6150-6160.
56. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, et al. (2003) DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305: 115-123. (Pubitemid 36062817)
57. Winkler M, Bertram S, Gnirss K, Nehlmeier I, Gawanbacht A, et al. (2012) Influenza A virus does not encode a tetherin antagonist with Vpu-like activity and induces IFN-dependent tetherin expression in infected cells. PLoS One 7: e43337.
58. Kupcsik L (2011) Estimation of cell number based on metabolic activity: the MTT reduction assay. Methods Mol Biol 740: 13-19.